66630-70-4

Usage

Uses

Used in Pharmaceutical Industry:
2-PHENYL-3H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID is used as a potential therapeutic agent for its anti-inflammatory properties, aiming to alleviate inflammation-related conditions and diseases.
Used in Oncology:
In the field of oncology, 2-PHENYL-3H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID is used as a potential anti-cancer agent, being studied for its ability to target and inhibit the growth of cancer cells, offering a new avenue for cancer treatment.
Used in Neurological Disorders Research:
2-PHENYL-3H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID is used as a research compound for its potential as a ligand for the benzodiazepine receptor, which may lead to the development of new medications for the treatment of neurological disorders.
Additional research is ongoing to further explore the potential pharmaceutical applications of 2-PHENYL-3H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID, indicating its versatility and importance in the field of medicinal chemistry.

InChI:InChI=1/C14H10N2O2/c17-14(18)10-6-7-11-12(8-10)16-13(15-11)9-4-2-1-3-5-9/h1-8H,(H,15,16)(H,17,18)

Upstream product

• 100-52-7 benzaldehyde 
• 619-05-6 3,4-diaminobenzoic acid 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 69570-97-4 methyl 2-phenyl-1H-benzo[d]imidazole-6-carboxylate 
• 37466-90-3 ethyl 3,4-diaminobenzoate 
• 65-85-0 benzoic acid 
• 2963-65-7 5-methyl-2-phenyl-1H-1,3-benzimidazole 
• 69570-97-4 2-phenyl-1H-benzimidazole-5-carboxylic acid methyl ester 
• 4657-12-9 sodium hydroxy(phenyl)methanesulfonate 

Downstream Products

• 1467592-47-7 5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenyl-1H-benzimidazole 
• 1259500-92-9 C₅₅H₈₁N₅O₁₆ 
• 1259500-78-1 4''-O-(2-phenyl-1H-benzimidazole-5-carbonyl)hydrazinecarbonylclarithromycin 
• 1031414-84-2 C₂₈H₂₅N₃O₄ 

Relevant academic research and scientific papers

[Re(η6-C6H5-benzimidazole)2]+ and Derivatives as Dye Mimics; Synthesis, UV Absorption Studies and DFT Calculations

Functionalizations of highly oxidation and hydrolysis stable mono-cationic rhenium bis-arene complexes [Re(η6-C6H6)2]+ are of great interest. We directly built up structural features of the well-known Hoechst Dye on the coordinated arenes as a model for prospective DNA minor groove binding studies. Extensions of the aromatic bis-arene unit with functionalized and derivatized benzimidazole moieties resulted in a deep orange colour of the complexes, showing UV/Vis absorption spectra with multiple transition maxima. These have been assigned with support of DFT calculations to gain information about their charge transfer natures. The different transitions of the complexes, which are either intra-ligand, ligand-to-ligand or metal-to-ligand charge transitions, were additionally compared and discussed with the spectra of the corresponding free ligands.

Structure-Guided Synthesis and Evaluation of Small-Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain

The tandem BRCT domains (tBRCT) of BRCA1 engage phosphoserine-containing motifs in target proteins to propagate intracellular signals initiated by DNA damage, thereby controlling cell cycle arrest and DNA repair. Recently, we identified Bractoppin, the fi

PIPERAZINE DERIVATIVES AS MAGL INHIBITORS

The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION

The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling

Intracellular signals triggered by DNA breakage flow through proteins containing BRCT (BRCA1 C-terminal) domains. This family, comprising 23 conserved phosphopeptide-binding modules in man, is inaccessible to small-molecule chemical inhibitors. Here, we develop Bractoppin, a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain, which selectively inhibits substrate binding with nanomolar potency in vitro. Structure-activity exploration suggests that Bractoppin engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket that is distinct in structurally related BRCT domains, conferring selectivity. In cells, Bractoppin inhibits substrate recognition detected by F?rster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. But damage-induced MDC1 recruitment, single-stranded DNA (ssDNA) generation, and TOPBP1 recruitment remain unaffected. Thus, an inhibitor of phosphopeptide recognition selectively interrupts BRCA1 tBRCT-dependent signals evoked by DNA damage. Periasamy et al. report the development of Bractoppin, a drug-like inhibitor of phosphopeptide recognition by the BRCA1 tBRCT domain, opening avenues to block intracellular signaling via a family of related targets.

Chromium(III)-salen complex nanoparticles on AlPO4: as an efficient heterogeneous and reusable nanocatalyst for mild synthesis of highly functionalized piperidines, 2-arylbenzimidazoles, and 2-arylbenzothiazoles

Abstract: A simple, convenient, and highly efficient multicomponent one-pot synthesis of highly functionalized piperidines has been developed via tandem reactions of β-keto esters, aromatic aldehydes, and various amines in ethanol at room temperature using catalytic amount (10?mol%) of a chromium(III)-salen complex nanoparticles supported on AlPO4. The heterogeneous catalyst exhibited excellent activity and reusability (up to 8 times) in the synthesis of highly functionalized piperidines. Also, synthesis of 2-arylbenzimidazoles and 2-arylbenzothiazoles have been efficiently developed under mild condition from o-phenylenediamines or 2-aminothiophenol with aryl aldehydes via one-step process using catalytic amount (2.0?mol%) of nanocatalyst in air atmosphere as a green oxidant. The heterogeneous catalyst was characterized by scanning electron microscopy, atomic force microscopy, inductively coupled plasma spectrometry, thermogravimetry for analysis of nitrogen adsorption, and FT-IR spectroscopy. Graphical Abstract: [Figure not available: see fulltext.].

Significant facilitation of metal-free aerobic oxidative cyclization of imines with water in synthesis of benzimidazoles

A simple, convenient, and environmentally benign protocol for the synthesis of benzimidazoles from ortho-phenylenediamines and aldehydes via aerobic oxidation was developed in wet organic solvents. Notably, water significantly accelerated this transformation, which allowed us to achieve this important transformation without the assistance of any metal catalysts and other co-oxidants. Mechanistic studies suggested that water acts as the nucleophilic catalyst for this transformation by the conversion of disfavored 5-endo-trig cyclization of imines to favored 5-exo-tet cyclization via tetrahedral intermediates and the subsequent aerobic oxidation of the resulting benzimidazolines affords benzimidazoles.

FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS

Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or h

Synthetic Method of Benzimidazole via Aerobic Oxidation

The present invention relates to a method which naturally synthesizes benzimidazole by reacting aryl diamine and aldehyde through using aerobic oxidative cyclization which uses water or alkali metal halide as a catalyst, and oxygen or oxygen in the air as an oxidizing agent, under DMF or an alcohol solvent.

Synthesis and biological evaluation of novel benzimidazole derivatives bearing a heterocyclic ring at 4/5 position

A series of novel benzimidazole derivatives bearing a heterocyclic ring as oxadiazole (21-32), thiadiazole (33-34), triazole (35-36) were synthesized and evaluated for their activities against Coxsackie virus B3 and B6 in Vero cells. Compounds 21-26, 31-36 with moieties of 2'-pyridyl, 3'-pyridyl and 4'-pyridyl at the 2-position and oxadiazoles, thiadiazole, or triazole substituent at the 4- or 5-position generally displayed activities against CVB3 and CVB6. Especially compound 24 (IC50 = 1.08 μg/mL, SI = 61.7 against CVB3) was the promising candidate as lead compound for anti-enteroviral drug. It was observed in the incorporation of heterocyclic rings in benzimidazole at the 5-position could enhance their biological activities.